Regulation of Apo-2 ligand/TRAIL expression in NK cells - Involvement in NK cell-mediated cytotoxicity

Cytokine

Volumn 11, Issue 9, 1999, Pages 664-672

  Johnsen, Ann Charlotte ^a   Haux, Johan ^a   Steinkjer, Bjørg ^a   Nonstad, Unni ^a   Egeberg, Kjartan ^a   Sundan, Anders ^a   Ashkenazi, Avi ^b   Espevik, Terje ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b GENENTECH INC   (United States)

Author keywords

Apo 2 ligand; Apoptosis; Cytotoxicity; NK; TRAIL

Indexed keywords

CYTOKINE; INTERLEUKIN 2; MESSENGER RNA; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CELL MEDIATED CYTOTOXICITY; CYTOLYSIS; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0032869392     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0489     Document Type: Article

References (37)

1. Nagata S, Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
2. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science. 264:1994;667-668.
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
4. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumour necrosis factor cytokine family. J Biol Chem. 271:1996;12687-12690.
5. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol. 28:1998;143-152.
6. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol. 6:1996;750-752.
7. Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, Tijoe IM, Smith CA, Herzenberg LA. Interleukin-1 beta converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection. TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection. J Exp Med. 186:1997;1365-1372.
8. Thomas WD, Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J Immunol. 161:1998;2195-2200.
9. Wen LP, Fahrni JA, Troie S, Guan JL, Orth K, Rosen GD. Cleavage of focal adhesion kinase by caspases during apoptosis. J Biol Chem. 272:1997;26056-26061.
10. Snell V, Clodi K, Zhao S, Goodwin R, Thomas EK, Morris SW, Kadin ME, Cabanillas F, Andreeff M, Younes A. Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. Br J Haematol. 99:1997;618-624.
11. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 85:1996;817-827.
12. Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol. 137:1997;221-229.
13. Medvedev AE, Johnsen AC, Haux J, Steinkjer B, Egeberg K, Lynch DH, Sundan A, Espevik T. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine. 9:1997;394-404.
14. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, Motoyoshi K, Mizuki M, Tagawa S, Ohga S, Hatake K, Drummond AH, Nagata S. Fas ligand in human serum. Nat Med. 2:1996;317-322.
15. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 377:1995;630-632.
16. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 270:1995;1189-1192.
17. Marsters SA, Sheridan JP, Pitti RM, Huang AD, Skubatch AD, Baldwin AD, Yuan AD, Gurney AD, Goddard AD. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol. 7:1997;1003-1006.
18. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818-821.
19. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science. 276:1997;111-113.
20. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a Receptor for the Cytotoxic Ligand TRAIL. J Biol Chem. 273:1998;14363-14367.
21. Schneider P, Thome M, Burns K, Bodmer JL, Hofmann K, Kataoka T, Holler N, Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 7:1997;831-836.
22. Moretta A. Molecular mechanisms in cell-mediated cytotoxicity. Cell. 90:1997;13-18.
23. Lanier, LL, Phillips, JH, Hackett, J, Jr. Tutt, M, Kumar, V, 1986, Natural killer cells: definition of a cell type rather than a function, J Immunol, 1987, 138, 996, 1987, 138, 2745, J Immunol, 137, 2735, 2739.
24. Lanier, LL, Phillips, JH, Hackett, J, Jr. Tutt, M, Kumar, V, 1986, Natural killer cells: definition of a cell type rather than a function, J Immunol, 1987, 138, 996, 1987, 138, 2745, J Immunol, 137, 2735, 2739.
25. Naume B, Nonstad U, Steinkjer B, Funderud S, Smeland E, Espevik T. Immunomagnetic isolation of NK and LAK cells. J Immunol Methods. 136:1991;1-9.
26. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol. 7:1997;693-696.
27. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol. 136:1986;4480-4486.
28. Phillips JH, Lanier LL. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med. 164:1986;814-825.
29. Braun MY, Lowin B, French L, Acha Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med. 183:1996;657-661.
30. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
31. Smith D, Sieg S, Kaplan D. Technical note: Aberrant detection of cell surface Fas ligand with anti- peptide antibodies. J Immunol. 160:1998;4159-4160.
32. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K, Ramsdell F, Lynch DH. Fas transduces activation signals in normal human T lymphocytes. J Exp Med. 178:1993;2231-2235.
33. Espevik T, Sundan A, Liabakk NB, Waage A. Cytokine interaction and clinical response. Kinney JM, Tucker HN. Organ Metabolism and Nutrition. 1994;165-180 Raven Press, Ltd. New York.
34. Kiener PA, Davis PM, Rankin BM, Klebanoff SJ, Ledbetter JA, Starling GC, Liles WC. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J Immunol. 159:1997;1594-1598.
35. Gough NM. Rapid and quantitative preparation of cytoplasmic RNA from small numbers of cells. Anal Biochem. 173:1988;93-95.
36. Naume B, Johnsen AC, Espevik T, Sundan A. Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7 and interleukin-12. Eur J Immunol. 23:1993;1831-1838.
37. Hatam L, Schuval S, Bonagura VR. Flow cytometric analysis of natural killer cell function as a clinical assay. Cytometry. 16:1994;59-68.